AXL and non-small cell lung carcinoma: LDOC1 depletion enhanced the activation of EGFR, HER2, HER3, and AXL, and LDOC1 downregulation was strongly correlated with poor overall survival in patients with EGFRM advanced NSCLC who received gefitinib.